Pyrazinamide and Hydroxychloroquine (AI-Optimised)
Phase 2Small molecule
Pyrazinamide and Hydroxychloroquine (AI-Optimised) is one of 32 small molecule programs targeting Pulmonary Tuberculosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Pulmonary Tuberculosis
#DrugCompanyPhaseTrials
1Priftin
SanofiApproved
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Myambutol
VVA Greater Los Angeles Healthcare System
Approved
Calciferol
Jazz PharmaceuticalsApproved
Avelox
BayerPhase 3
Decadron
AAspen Global Incorporated
Approved
Rayos
RRoxane Laboratories
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMinistry of Health, Saudi Arabia